Kardigan, Inc. reported financial results for the fiscal quarter ended June 30, 2026, posting a net loss of $116.2 million compared to $57.4 million in the prior year period. Research and development expenses increased to $56.4 million from $35.8 million due to clinical trial costs and headcount growth, while general and administrative expenses decreased to $18.9 million from $21.3 million. The company ended the quarter with a cash position of $660.7 million, supported by $460 million in gross proceeds from its initial public offering completed in June 2026. Clinically, Phase 3 enrollment for danicamtiv (KINSHIP-DCM) is underway, and the first patient was randomized in the tonlamarsen (KARDINAL-ASH) Phase 2 trial. Kardigan operates as a clinical-stage precision therapeutics company developing medicines targeting cardiovascular diseases with no approved treatments.

Kardigan, Inc. filed its third amended and restated certificate of incorporation on June 22, 2026, in connection with its initial public offering. The amended certificate authorizes 700,000,000 shares of common stock, consisting of 500,000,000 voting and 200,000,000 non-voting shares, and 10,000,000 shares of undesignated preferred stock. The filing also eliminates stockholder rights to take action by written consent and to call special meetings. Additionally, the company adopted amended and restated bylaws to establish formal stockholder meeting procedures and advance notice requirements for proposals. Kardigan, Inc. is a company undergoing an initial public offering.